Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas

World Journal of Surgery

Volumn 38, Issue 6, 2014, Pages 1343-1352

  Subramanian, Chitra ^a   Zhang, Huaping ^b   Gallagher, Robert ^b   Hammer, Gary ^c   Timmermann, Barbara ^b   Cohen, Mark ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WITHAFERIN A; WITHANOLIDE;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; PROCEDURES; SENSITIVITY AND SPECIFICITY; TUMOR CELL CULTURE;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; WITHANOLIDES;

EID: 84902108568     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-014-2532-0     Document Type: Article

References (35)

1. Michalkiewicz E, Sandrini R, Figueiredo B et al (2004) Clinical and outcome characteristics of children with adrenocortical tumors: a report from the international pediatric adrenocortical tumor registry. J Clin Oncol 22:838-845
2. Schteingart DE, Doherty GM, Gauger PG et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667-680
3. Berruti A, Terzolo M, Sperone P et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657-666
4. Berthon A, Sahut-Barnola I, Lambert-Langlais S et al (2010) Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 19:1561-1576
5. Heaton JH, Wood MA, Kim AC et al (2012) Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and beta-catenin. Am J Pathol 181:1017-1033
6. Simon DP, Giordano TJ, Hammer GD (2012) Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. Clin Cancer Res 18:2452-2464
7. Demeure MJ, Bussey KJ, Kirschner LS (2011) Targeted therapies for adrenocortical carcinoma: iGF and beyond. Horm Cancer 2(6):385-392
8. Stigliano A, Cerquetti L, Sampaoli C et al (2012) Current and emerging therapeutic options in adrenocortical cancer treatment. J Oncol 2012:408131
9. Giordano TJ (2010) Adrenocortical tumors: an integrated clinical, pathologic, and molecular approach at the University of Michigan. Arch Pathol Lab Med 134:1440-1443
10. Sarkar FH, Li Y (2009) Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 35:597-607
11. Gunasekera SP, Kinghorn AD, Cordell GA, Farnsworth NR (1981) Plant anticancer agents. XIX Constituents of Aquilaria malaccensis. J Nat Prod 44(5):569-572
12. Sahai M, Kirson I (1984) Withaphysalin D, a new withaphysalin from Physalis minima Linn. var. indica. J Nat Prod 47(3):527-529
13. Zhang H, Samadi AK, Rao KV, Cohen MS, Timmermann BN (2011) Cytotoxic oleanane-type saponins from Albizia inundata. J Nat Prod 74(3):477-482
14. Grogan PT, Sleder KD, Samadi AK, Zhang H, Timmermann BN, Cohen MS (2013) Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest New Drugs 31(3):545-557
15. Samadi AK, Bazzill J, Zhang X, Gallagher R, Zhang H, Gollapudi R, Timmermann BN, Cohen MS (2012) Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway. Surgery 152(6):1238-1247
16. Samadi AK, Mukerji R, Shah A, Timmermann BN, Cohen MS (2010) A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo. Surgery 148(6):1228-1236
17. Samadi AK, Tong X, Mukerji R, Zhang H, Timmermann BN, Cohen MS (2010) Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma. J Nat Prod 73(9):1476-1481
18. Zhang X, Mukerji R, Samadi AK et al (2011) Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells. BMC Complement Altern Med 11:84
19. Samadi AK, Cohen SM, Mukerji R et al (2012) Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation. Tumour Biol 33:1179-1189
20. Samadi A, Loo P, Mukerji R et al (2009) A novel HSP90 modulator with selective activity against thyroid cancers in vitro. Surgery 146:1196-1207
21. Zhang H, Samadi AK, Gallagher RJ et al (2011) Cytotoxic withanolide constituents of Physalis longifolia. J Nat Prod 74:2532-2544
22. Zhang H, Samadi AK, Cohen MS, Timmermann BN (2012) Antiproliferative withanolides from the Solanaceae: a structure-activity study. Pure Appl Chem 84:1353-1367
23. Mayola E, Gallerne C, Esposti DD et al (2011) Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis 16:1014-1027
24. Almeida MQ, Fragoso MC, Lotfi CF et al (2008) Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metabolism 93:3524-3531
25. Barlaskar FM, Spalding AC, Heaton JH et al (2009) Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94:204-212
26. Koduru S, Kumar R, Srinivasan S, Evers MB, Damodaran C (2010) Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther 9(1):202-210
27. Yu Y, Hamza A, Zhang T et al (2010) Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 79:542-551
28. Santagata S, Xu YM, Wijeratne EM et al (2012) Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol 7:340-349
29. Gotink KJ, Broxterman HJ, Labots M et al (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17:7337-7346
30. Manara MC, Nicoletti G, Zambelli D et al (2010) NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16:530-540
31. Roccaro AM, Sacco A, Husu EN et al (2010) Dual targeting of the PI3 K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115:559-569
32. Chen X, Stoeck A, Lee SJ et al (2010) Jagged1 expression regulated by Notch3 and Wnt/beta-catenin signaling pathways in ovarian cancer. Oncotarget 1:210-218
33. Rodilla V, Villanueva A, Obrador-Hevia A et al (2009) Jagged 1 is the pathological link between Wnt and notch pathways in colorectal cancer. Proc Natl Acad Sci USA 106:6315-6320
34. Guilmeau S, Flandez M, Mariadason JM et al (2010) Heterogeneity of Jagged1 expression in human and mouse intestinal tumors: implications for targeting Notch signaling. Oncogene 29:992-1002
35. Durand J, Lampron A, Mazzuco TL et al (2011) Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations. J Clin Endocrinol Metab 96:E1206-E1211